| Meloney Oliveira, MD | |
|
7981 Gladiolus Dr, Fort Myers, FL 33908-4154 | |
| (239) 939-0999 | |
| (239) 425-0795 |
| Full Name | Meloney Oliveira |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Nephrology |
| Location | 7981 Gladiolus Dr, Fort Myers, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952897084 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 125.072806 (Illinois) | Secondary |
| 207RN0300X | Internal Medicine - Nephrology | ME159320 (Florida) | Primary |
| Entity Name | Mogilishetty Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972117109 PECOS PAC ID: 0648680579 Enrollment ID: O20201105000038 |
News Archive
FEI is pleased to announce that researchers at the NIH-FEI Living Lab for Structural Biology have achieved breakthrough biological results, using FEI's Titan Krios™ transmission electron microscope (TEM), to elucidate the structural mechanism by which glutamate receptors participate in the transmission of signals between neurons in the brain. Their work is described in Nature, "Structural Mechanism of Glutamate Receptor Activation and Desensitization," by Meyerson, et al., (DOI: 10.1038/nature13603), http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13603.html .
In salt-sensitive hypertension, immune cells gather in the kidneys and shoot out free radicals, heightening blood pressure and damaging this pair of vital organs, scientists report.
Ingen Technologies, Inc., an emerging medical device manufacturer developing innovative solutions for the respiratory market, with a new patented and proprietary medical product line targeting the $8B respiratory market, announced today that the company revenues have increased from $10,401 reported in May 31, 2009, to $128,917 ending May 31, 2010. This is an increase of 1,139%.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has achieved the target enrollment of the minimum of 100 evaluable relapsed or refractory peripheral T-cell lymphoma (PTCL) patients in the BELIEF registration trial.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Meloney Oliveira, MD 7981 Gladiolus Dr, Fort Myers, FL 33908-4154 Ph: () - | Meloney Oliveira, MD 7981 Gladiolus Dr, Fort Myers, FL 33908-4154 Ph: (239) 939-0999 |
News Archive
FEI is pleased to announce that researchers at the NIH-FEI Living Lab for Structural Biology have achieved breakthrough biological results, using FEI's Titan Krios™ transmission electron microscope (TEM), to elucidate the structural mechanism by which glutamate receptors participate in the transmission of signals between neurons in the brain. Their work is described in Nature, "Structural Mechanism of Glutamate Receptor Activation and Desensitization," by Meyerson, et al., (DOI: 10.1038/nature13603), http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13603.html .
In salt-sensitive hypertension, immune cells gather in the kidneys and shoot out free radicals, heightening blood pressure and damaging this pair of vital organs, scientists report.
Ingen Technologies, Inc., an emerging medical device manufacturer developing innovative solutions for the respiratory market, with a new patented and proprietary medical product line targeting the $8B respiratory market, announced today that the company revenues have increased from $10,401 reported in May 31, 2009, to $128,917 ending May 31, 2010. This is an increase of 1,139%.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has achieved the target enrollment of the minimum of 100 evaluable relapsed or refractory peripheral T-cell lymphoma (PTCL) patients in the BELIEF registration trial.
› Verified 1 days ago
Anthony A Mcfarlane, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 8960 Colonial Center Dr Ste 302, Fort Myers, FL 33905 Phone: 239-343-9700 Fax: 239-343-9699 | |
Scott Francis Allen, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1550 Barkley Cir, Fort Myers, FL 33907 Phone: 239-938-2000 | |
Dr. Jyothsna Priyadarshini Bandaru, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3725 Piazza Dr Apt 202, Fort Myers, FL 33916 Phone: 000-000-0000 | |
Dr. Daniel Morales, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 9981 S Healthpark Dr, Fort Myers, FL 33908 Phone: 239-343-2052 Fax: 239-343-5348 | |
Richard A Chazal, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 9800 S Health Park Dr, Suite 320, Fort Myers, FL 33908 Phone: 239-343-6350 Fax: 239-343-6358 | |
Dr. James M Toomey, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 13340 Metro Pkwy Ste 310, Fort Myers, FL 33966 Phone: 239-343-1448 Fax: 239-343-1449 | |
Charles M Callahan, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2780 Cleveland Ave Ste 809, Fort Myers, FL 33901 Phone: 239-343-9680 Fax: 239-343-4178 |